Biosafety Monitoring of Patients Receiving Intracerebral Injections of Murine Retroviral Vector Producer Cells
- 20 May 1998
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (8) , 1165-1172
- https://doi.org/10.1089/hum.1998.9.8-1165
Abstract
Patients with recurrent malignant brain cancer, who were receiving gene therapy by intracerebral injection of murine retroviral vector producer cells (VPCs), were monitored for the presence of replication-competent retrovirus (RCR). RCR sequences were not detected by polymerase chain reaction (PCR) in any of the 608 peripheral blood leukocyte (PBL) samples analyzed. Vector DNA sequences were detected transiently in PBL samples from a subset of 34 patients. Humoral immune responses to a retroviral core protein p30 and murine VPC were detected in some patients, most frequently in patients receiving repeated administrations of VPC. RCR was not detected in biological assays of PBLs from 41 patients who had either anti-retroviral antibodies in sera and/or vector DNA in PBLs. Our data suggest that in situ generation of RCR was not detected following intracerebral inoculation of VPCs in any of the 128 patients evaluated.Keywords
This publication has 21 references indexed in Scilit:
- Evaluation of Recommendations for Replication-Competent Retrovirus Testing Associated with Use of Retroviral VectorsHuman Gene Therapy, 1997
- Gene Therapy in the United States: A Five-Year Status ReportHuman Gene Therapy, 1996
- Bystander Tumoricidal Effect in the Treatment of Experimental Brain TumorsNeurosurgery, 1994
- Characterization of a Replication-Competent Retrovirus Resulting from Recombination of Packaging and Vector SequencesHuman Gene Therapy, 1994
- Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Iowa Methodist Medical Center, Des Moines, IowaHuman Gene Therapy, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Herpes Simplex-1 Virus Thymidine Kinase Gene Is Unable to Completely Eliminate Live, Nonimmunogenic Tumor Cell VaccinesJournal of Immunotherapy, 1992
- NF-kappa B-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts.The Journal of Experimental Medicine, 1992
- No Retroviremia or Pathology in Long-Term Follow-Up of Monkeys Exposed to a Murine Amphotropic RetrovirusHuman Gene Therapy, 1991
- Amphotropic Murine Leukemia Retrovirus Is Not an Acute Pathogen for PrimatesHuman Gene Therapy, 1990